The announcement of the launch coincides with Beemine's participation in Expopharm Düsseldorf (September 16–18, 2025), the most important pharmaceutical trade fair in Europe. The company will have its own space at booth C40, where it will present its medical cannabis catalog and share its vision for the future with professionals, distributors, and investors.
The presence at Expopharm consolidates Beemine's commitment to the German market and marks the beginning of a new stage: the integration of medical cannabis into the European healthcare system with rigor, safety, and transparency.
What is medical cannabis?
Medical cannabis refers to the use of the cannabis plant and its derivatives—mainly cannabinoids like THC and CBD—for medical purposes under prescription and health control. These products are used as part of supervised treatments for various pathologies, from chronic pain to neurological disorders, always in regulated environments and with pharmaceutical quality guarantees.
Unlike recreational use, medical cannabis is subject to strict standards for cultivation, production, dispensing, and traceability. Each batch must meet safety and purity criteria that allow doctors and patients to rely on a dependable and consistent medicine.
The Beemine Lab paves the way in medical cannabis
In September 2025, The Beemine Lab announced its entry into the German market with a complete line of medical cannabis, becoming the first Spanish laboratory with a commercial brand in this segment. This move reinforces Beemine's vocation to lead innovation in the sector and marks a before and after in its internationalization strategy.
Germany: the European engine of medical cannabis
Germany has consolidated its position as the largest medical cannabis market in Europe and one of the most dynamic in the world. Since the prescription of medical cannabis was authorized in 2017, the country has built a regulated access system through pharmacies under medical prescription.
In 2024, the German market reached 500 million euros in sales, and it is expected to exceed 1 billion euros by 2027, which positions it as the regulatory and commercial epicenter of the continent. Currently, more than 200,000 German patients have access to medical cannabis treatments, mainly for chronic pain, multiple sclerosis, palliative care, and resistant epilepsies.
The BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) strictly supervises the process: from the authorization of cultivation to importation, traceability, dispensing in pharmacies, and pharmaceutical quality control. This robust regulatory structure makes Germany an international benchmark and the main export market for medical cannabis producers from around the world.
For Beemine, entering this context means not only accessing a growing market but also positioning itself as a reliable European player in the most demanding environment.
Our medical cannabis catalog
https://thebeeminelab.org/Medical.html
Medicinal Flowers
Beemine offers a diverse range of medicinal cannabis flowers, standardized and traceable, with a shelf life of between 12 and 18 months, in formats from 10g to 1,500g.
Main varieties:
TBL 001 (22% THC)
TBL 002 (24% THC)
TBL 003 (20% THC)
TBL 004 (26% THC)
TBL 005 (25% THC)
TBL 006 (24% THC)
TBL 007 (21% THC)
Medicinal Extracts
In addition to flowers, Beemine has a line of THC:CBD in MCT extracts, available in amber bottles of 10, 30, and 100 mL, with a shelf life of 12 to 30 months.
Main formulations:
50:50 THC:CBD
25:25 THC:CBD
20:80 THC:CBD
20:40 THC:CBD
20:10 THC:CBD
This catalog allows for covering a wide spectrum of therapeutic needs, always under medical prescription and within a regulated framework.
Situation of medical cannabis in Spain
While Germany is advancing rapidly, the situation in Spain is different. Although the AEMPS (Spanish Agency of Medicines and Medical Devices) is the competent authority regarding cannabis, to date, access to medical cannabis in Spain remains limited.
In 2022, Congress approved the mandate to regulate its therapeutic use, but the actual implementation has been hampered by bureaucratic delays. As of 2025, patients can only access it in very specific settings, mainly through clinical trials or hospital research programs, without a widespread dispensing channel in pharmacies.
This puts Spain at a disadvantage compared to countries like Germany, Portugal, or Italy, where medical cannabis is already integrated into the healthcare system under prescription.
For Beemine, this contrast represents both a challenge and an opportunity: to contribute to the regulatory debate in Spain and, at the same time, to make headway in the most advanced European markets.
Regulatory Roadmap: step by step towards 2026
Entry into the German market is not immediate. Beemine is currently working on a regulatory roadmap, in coordination with the AEMPS and the BfArM.
The process involves complying with strict requirements for quality, safety, traceability, and distribution. Therefore, the company anticipates that, due to bureaucratic timelines, the first commercial transactions of medical cannabis may take place starting in the second quarter of 2026.
Until then, the focus is on preparing the documentary, technical, and logistical infrastructure to ensure full compliance with European regulations.
Innovation and sustainability in medical cannabis
Beemine's commitment goes beyond regulatory compliance. The company integrates sustainability as a strategic focus, working with suppliers who guarantee good agricultural practices, reduction of environmental impact, and pharmaceutical quality.
In addition, the accumulated experience with the OTC line—especially with the Alivium CBD range for muscle and joint recovery—allows Beemine to transfer learnings in formulation, pharmacy distribution, and relationships with healthcare professionals to its future medicinal portfolio.
